Immunotherapy

Nivolumab Shows Durable Activity in Subgroups of Patients with Metastatic CRC

Charles Bankhead

May 2018, Vol 8, No 5 - Immunotherapy

Almost 66% of patients who had previously received treatment for metastatic co­lorectal cancer (mCRC) and DNA mismatch repair deficiency (dMMR) derived clinical benefit from monotherapy with nivolumab (Opdivo), long-term follow-up from a prospective clinical trial showed. After a median follow-up of almost 2 years, 34% of 74 evaluable patients had objective responses, including 7 complete responses. [ Read More ]

Understanding Immunotherapy Late Adverse Effects in Cancer Survivors

Meg Barbor, MPH

April 2018, Vol 8, No 4 - Immunotherapy, Survivorship

Because of the novel mechanisms of action of immunotherapies, extended treatment period, and unique toxicities, cancer treatment with immunotherapy warrants special consideration from a survivorship standpoint, suggested Katy K. Tsai, MD, Clinical Instructor, Division of Hematology/Oncology, University of California, San Francisco (UCSF), at the 2018 Cancer Survivorship Symposium. [ Read More ]

Switching on the Light: A Model Immunotherapy Program for Oncology Practices

Gail Thompson

February 2018, Vol 8, No 2 - Immunotherapy

Immunotherapy is one of the hottest concepts in oncology care. Also called biologic therapy, this type of cancer treatment boosts the body’s own natural defenses to fight cancers. Ann M. McGreal, RN, OCN, Oncology Nurse Clinician, and Sigrun Hallmeyer, MD, Senior Executive Director, Advocate Medical Group, Park Ridge, IL, shared their experience with immunotherapy at the ACCC National Oncology Conference in October 2017 in Nashville. [ Read More ]

Adding Indoximod to Pembrolizumab Boosts Immune Response in Melanoma

Phoebe Starr

June 2017, Vol 7, No 6 - Immunotherapy

Washington, DC—Adding the investigational drug indoximod, an indole­amine 2,3-dioxygenase (IDO) pathway inhibitor, to the checkpoint inhibitor pembrolizumab (Keytruda) led to higher response rates in patients with advanced melanoma than what is reported with pembrolizumab monotherapy, said lead investigator Yousef Zakharia, MD, Clinical Assistant Professor of Internal Medicine, Division of Hema­tology, Oncology and Blood and Marrow Transplantation, University of Iowa, Iowa City, at the 2017 American Association for Cancer Research meeting. [ Read More ]

New Research Explains Reasons for Latent Metastasis, Charting a Way for Novel Immunotherapies

Jessica Miller

March 2017, Vol 7, No 3 - Immunotherapy

Cancer often returns years after successful treatment, and it often metastasizes to new organs, which is known as latent metastasis. Certain cancer cells, recently labeled as latency competent cancer (LCC) cells, are capable of becoming dormant for extended periods of time, thereby evading the body’s immunity and leading to cancer recurrence in distant organs after the initial remission. [ Read More ]